Use of anti-malarial drugs and the risk of developing eye disorders. Schneider, C., Adamcova, M., Jick, S. S., Schlagenhauf, P., Miller, M. K., Rhein, H., & Meier, C. R. Travel Medicine and Infectious Disease, 12(1):40--47, February, 2014. doi abstract bibtex BACKGROUND: Ocular toxicity was described in the late 1950s for some anti-malarial drugs, but only limited information is available on the comparison of ocular toxicity of different anti-malarials. METHODS: We conducted a follow-up study with a nested case-control analysis using the General Practice Research Database to compare the risk of developing a first-time diagnosis of an eye disorder during exposure of mefloquine, chloroquine and/or proguanil or atovaquone/proguanil use to non-users. We calculated incidence rates with 95% confidence intervals (CI) and odds ratios using multivariate conditional logistic regression analyses. RESULTS: We included 83,148 patients and identified 652 cases with an incident eye disorder. The incidence rates with 95% CI of all eye disorders combined in users of mefloquine, chloroquine and/or proguanil, atovaquone/proguanil or travellers not using anti-malarials were 5.3 (4.3-6.5), 7.1 (5.0-9.9), 6.3 (5.6-7.2) and 5.1 (4.6-5.7), per 1000 person-years, respectively. As compared to non-users of anti-malarials, the adjusted odds ratio with 95% CI in the nested case-control analysis for users of mefloquine, chloroquine and/or proguanil, or atovaquone/proguanil were 1.33 (1.01-1.75), 1.61 (1.06-2.45), and 1.25 (1.03-1.52), respectively. CONCLUSIONS: The study provides evidence that there was an increased risk of eye disorders in users of all anti-malarials compared to non-users of anti-malarials.
@article{schneider_use_2014,
title = {Use of anti-malarial drugs and the risk of developing eye disorders},
volume = {12},
issn = {1873-0442},
doi = {10.1016/j.tmaid.2013.07.007},
abstract = {BACKGROUND: Ocular toxicity was described in the late 1950s for some anti-malarial drugs, but only limited information is available on the comparison of ocular toxicity of different anti-malarials.
METHODS: We conducted a follow-up study with a nested case-control analysis using the General Practice Research Database to compare the risk of developing a first-time diagnosis of an eye disorder during exposure of mefloquine, chloroquine and/or proguanil or atovaquone/proguanil use to non-users. We calculated incidence rates with 95\% confidence intervals (CI) and odds ratios using multivariate conditional logistic regression analyses.
RESULTS: We included 83,148 patients and identified 652 cases with an incident eye disorder. The incidence rates with 95\% CI of all eye disorders combined in users of mefloquine, chloroquine and/or proguanil, atovaquone/proguanil or travellers not using anti-malarials were 5.3 (4.3-6.5), 7.1 (5.0-9.9), 6.3 (5.6-7.2) and 5.1 (4.6-5.7), per 1000 person-years, respectively. As compared to non-users of anti-malarials, the adjusted odds ratio with 95\% CI in the nested case-control analysis for users of mefloquine, chloroquine and/or proguanil, or atovaquone/proguanil were 1.33 (1.01-1.75), 1.61 (1.06-2.45), and 1.25 (1.03-1.52), respectively.
CONCLUSIONS: The study provides evidence that there was an increased risk of eye disorders in users of all anti-malarials compared to non-users of anti-malarials.},
language = {eng},
number = {1},
journal = {Travel Medicine and Infectious Disease},
author = {Schneider, Cornelia and Adamcova, Miriam and Jick, Susan S. and Schlagenhauf, Patricia and Miller, Mary K. and Rhein, Hans-Georg and Meier, Christoph R.},
month = feb,
year = {2014},
pmid = {24035311},
keywords = {Adolescent, Adult, Aged, Antimalarials, Atovaquone, Case-Control Studies, Child, Child, Preschool, Chloroquine, Eye Diseases, Female, Great Britain, Humans, Infant, Malaria, Male, Mefloquine, Middle Aged, Proguanil, Risk, Travel Medicine, Young Adult, incidence},
pages = {40--47}
}
Downloads: 0
{"_id":"qcJruXSrHAiPwrCwb","bibbaseid":"schneider-adamcova-jick-schlagenhauf-miller-rhein-meier-useofantimalarialdrugsandtheriskofdevelopingeyedisorders-2014","downloads":0,"creationDate":"2017-08-15T09:38:11.865Z","title":"Use of anti-malarial drugs and the risk of developing eye disorders","author_short":["Schneider, C.","Adamcova, M.","Jick, S. S.","Schlagenhauf, P.","Miller, M. K.","Rhein, H.","Meier, C. R."],"year":2014,"bibtype":"article","biburl":"http://bibbase.org/zotero/veegee78","bibdata":{"bibtype":"article","type":"article","title":"Use of anti-malarial drugs and the risk of developing eye disorders","volume":"12","issn":"1873-0442","doi":"10.1016/j.tmaid.2013.07.007","abstract":"BACKGROUND: Ocular toxicity was described in the late 1950s for some anti-malarial drugs, but only limited information is available on the comparison of ocular toxicity of different anti-malarials. METHODS: We conducted a follow-up study with a nested case-control analysis using the General Practice Research Database to compare the risk of developing a first-time diagnosis of an eye disorder during exposure of mefloquine, chloroquine and/or proguanil or atovaquone/proguanil use to non-users. We calculated incidence rates with 95% confidence intervals (CI) and odds ratios using multivariate conditional logistic regression analyses. RESULTS: We included 83,148 patients and identified 652 cases with an incident eye disorder. The incidence rates with 95% CI of all eye disorders combined in users of mefloquine, chloroquine and/or proguanil, atovaquone/proguanil or travellers not using anti-malarials were 5.3 (4.3-6.5), 7.1 (5.0-9.9), 6.3 (5.6-7.2) and 5.1 (4.6-5.7), per 1000 person-years, respectively. As compared to non-users of anti-malarials, the adjusted odds ratio with 95% CI in the nested case-control analysis for users of mefloquine, chloroquine and/or proguanil, or atovaquone/proguanil were 1.33 (1.01-1.75), 1.61 (1.06-2.45), and 1.25 (1.03-1.52), respectively. CONCLUSIONS: The study provides evidence that there was an increased risk of eye disorders in users of all anti-malarials compared to non-users of anti-malarials.","language":"eng","number":"1","journal":"Travel Medicine and Infectious Disease","author":[{"propositions":[],"lastnames":["Schneider"],"firstnames":["Cornelia"],"suffixes":[]},{"propositions":[],"lastnames":["Adamcova"],"firstnames":["Miriam"],"suffixes":[]},{"propositions":[],"lastnames":["Jick"],"firstnames":["Susan","S."],"suffixes":[]},{"propositions":[],"lastnames":["Schlagenhauf"],"firstnames":["Patricia"],"suffixes":[]},{"propositions":[],"lastnames":["Miller"],"firstnames":["Mary","K."],"suffixes":[]},{"propositions":[],"lastnames":["Rhein"],"firstnames":["Hans-Georg"],"suffixes":[]},{"propositions":[],"lastnames":["Meier"],"firstnames":["Christoph","R."],"suffixes":[]}],"month":"February","year":"2014","pmid":"24035311","keywords":"Adolescent, Adult, Aged, Antimalarials, Atovaquone, Case-Control Studies, Child, Child, Preschool, Chloroquine, Eye Diseases, Female, Great Britain, Humans, Infant, Malaria, Male, Mefloquine, Middle Aged, Proguanil, Risk, Travel Medicine, Young Adult, incidence","pages":"40--47","bibtex":"@article{schneider_use_2014,\n\ttitle = {Use of anti-malarial drugs and the risk of developing eye disorders},\n\tvolume = {12},\n\tissn = {1873-0442},\n\tdoi = {10.1016/j.tmaid.2013.07.007},\n\tabstract = {BACKGROUND: Ocular toxicity was described in the late 1950s for some anti-malarial drugs, but only limited information is available on the comparison of ocular toxicity of different anti-malarials.\nMETHODS: We conducted a follow-up study with a nested case-control analysis using the General Practice Research Database to compare the risk of developing a first-time diagnosis of an eye disorder during exposure of mefloquine, chloroquine and/or proguanil or atovaquone/proguanil use to non-users. We calculated incidence rates with 95\\% confidence intervals (CI) and odds ratios using multivariate conditional logistic regression analyses.\nRESULTS: We included 83,148 patients and identified 652 cases with an incident eye disorder. The incidence rates with 95\\% CI of all eye disorders combined in users of mefloquine, chloroquine and/or proguanil, atovaquone/proguanil or travellers not using anti-malarials were 5.3 (4.3-6.5), 7.1 (5.0-9.9), 6.3 (5.6-7.2) and 5.1 (4.6-5.7), per 1000 person-years, respectively. As compared to non-users of anti-malarials, the adjusted odds ratio with 95\\% CI in the nested case-control analysis for users of mefloquine, chloroquine and/or proguanil, or atovaquone/proguanil were 1.33 (1.01-1.75), 1.61 (1.06-2.45), and 1.25 (1.03-1.52), respectively.\nCONCLUSIONS: The study provides evidence that there was an increased risk of eye disorders in users of all anti-malarials compared to non-users of anti-malarials.},\n\tlanguage = {eng},\n\tnumber = {1},\n\tjournal = {Travel Medicine and Infectious Disease},\n\tauthor = {Schneider, Cornelia and Adamcova, Miriam and Jick, Susan S. and Schlagenhauf, Patricia and Miller, Mary K. and Rhein, Hans-Georg and Meier, Christoph R.},\n\tmonth = feb,\n\tyear = {2014},\n\tpmid = {24035311},\n\tkeywords = {Adolescent, Adult, Aged, Antimalarials, Atovaquone, Case-Control Studies, Child, Child, Preschool, Chloroquine, Eye Diseases, Female, Great Britain, Humans, Infant, Malaria, Male, Mefloquine, Middle Aged, Proguanil, Risk, Travel Medicine, Young Adult, incidence},\n\tpages = {40--47}\n}\n\n","author_short":["Schneider, C.","Adamcova, M.","Jick, S. S.","Schlagenhauf, P.","Miller, M. K.","Rhein, H.","Meier, C. R."],"key":"schneider_use_2014","id":"schneider_use_2014","bibbaseid":"schneider-adamcova-jick-schlagenhauf-miller-rhein-meier-useofantimalarialdrugsandtheriskofdevelopingeyedisorders-2014","role":"author","urls":{},"keyword":["Adolescent","Adult","Aged","Antimalarials","Atovaquone","Case-Control Studies","Child","Child","Preschool","Chloroquine","Eye Diseases","Female","Great Britain","Humans","Infant","Malaria","Male","Mefloquine","Middle Aged","Proguanil","Risk","Travel Medicine","Young Adult","incidence"],"downloads":0},"search_terms":["use","anti","malarial","drugs","risk","developing","eye","disorders","schneider","adamcova","jick","schlagenhauf","miller","rhein","meier"],"keywords":["adolescent","adult","aged","antimalarials","atovaquone","case-control studies","child","child","preschool","chloroquine","eye diseases","female","great britain","humans","infant","malaria","male","mefloquine","middle aged","proguanil","risk","travel medicine","young adult","incidence"],"authorIDs":[],"dataSources":["FmCWXwJibZiWNzpdc"]}